Drug Trial Radar · NCT00705536
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
Last checked: Nov 20, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Dec 2007
Primary completion
Feb 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Health services research
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of Humalog (insulin lispro) or Humulin-R (recombinant human insulin) when administered as a single subcutaneous (SC) injection of 20 units (U) with or without coadministration of recombinant human hyaluronidase PH20 (rHuPH20). The study hypothesizes that the time required to reach maximum insulin concentration (tmax) when insulin is administered with rHuPH20 will be comparable or shorter than the time required without rHuPH20.
Conditions
- Diabetes Mellitus
Interventions
HumalogDrug
Humulin-RDrug
Recombinant human hyaluronidase PH20 (rHuPH20)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Maximum Serum Insulin Concentration (Tmax)Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
- Maximum Serum Insulin Concentration (Cmax)Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
- Area Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t'])Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
- Area Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20])Time frame: Predose and up to 48 minutes postdose during Stage 1, or up to 68 minutes postdose during Stage 2
- Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone)Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Diabetes and Glandular Disease Research, Inc.
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.